Analysts expect over 2020 rising revenue Regeneron Pharmaceuticals

Over the current book year the total revenue will be 8,15 billion USD (consensus estimates). This is slightly more than 2019's revenue of 7,86 billion USD.

Historical revenues and results Regeneron Pharmaceuticals plus estimates 2020

The analysts expect for 2020 a net profit of 3,31 billion USD. The majority of the analysts expects for this year a profit per share of 28,62 USD. Based on this the price/earnings-ratio is 20,96.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the pharmaceutical companies is a poor 0,38 percent.

Regeneron Pharmaceuticals's market capitalization is around 64,24 billion USD. The Regeneron Pharmaceuticals stock was the past 12 months quite unstable. Since last October the stock is even 101 percent higher. This year the stock price moved between 289 and 665 dollar.

Historical stock prices Regeneron Pharmaceuticals period 2007-2020

Click here for dividend Regeneron Pharmaceuticals. On Monday the stock closed at 599,88 USD.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.